A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis
- Registration Number
- NCT01904292
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This open-label, multicenter study will evaluate the pharmacokinetics, pharmacodynamics, and safety of subcutaneously administered tocilizumab in participants with Systemic Juvenile Idiopathic Arthritis (sJIA). Participants with body weight less than (\<) 30 kilograms (kg) will receive subcutaneous (SC) tocilizumab dose every 2 weeks (Q2W) and participants with body weight greater than or equal to (\>=) 30 kg will receive weekly (QW), for 52 weeks. Tocilizumab was administered every 10 days until pre-planned interim analysis was performed and changed to Q2W in participants with body weight \<30 kg.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 52
- Diagnosis of sJIA according to the International League of Associations for Rheumatology (ILAR) classification
- History of inadequate clinical response (in the opinion of the treating physician) to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and corticosteroids
- If a participant has received previous treatment with any biologic agents other than tocilizumab, these must have been discontinued according to the timelines defined by protocol prior to the baseline visit
- Participants currently receiving tocilizumab by the intravenous (IV) route of administration and with well-controlled disease do not require a period of discontinuation of IV tocilizumab and should have their first dose of SC tocilizumab administered on the date that their next IV tocilizumab infusion would be due
- Concurrent treatment with Disease Modifying Anti-Rheumatic Drugs (DMARDs) including methotrexate (MTX), NSAIDs, and oral corticosteroids are permitted at the discretion of the investigator
- Participants of reproductive potential must be willing to use highly effective contraceptive methods
- Prior discontinuation of IV tocilizumab because of inadequate clinical response or safety events (including hypersensitivity)
- Participants with poorly controlled disease (in the opinion of the treating physician) despite current treatment with IV tocilizumab
- sJIA that is well controlled by any treatment agent other than tocilizumab (Juvenile Arthritis Disease Activity Score of 71 Joints [JADAS-71] less than or equal to [<=] 3.8 with no fever)
- Participants who are wheelchair-bound or bedridden
- Any other auto-immune, rheumatic disease, or overlapping syndrome other than sJIA
- Lack of recovery from recent surgery or an interval of <6 weeks since surgery at the time of the screening visit
- Females who are pregnant, lactating, or intending to become pregnant during study conduct
- Any significant concurrent medical or surgical condition that would jeopardize the participant's safety or ability to complete the study
- Known Human Immunodeficiency Virus (HIV) infection or other acquired forms of immune compromise or inborn conditions characterized by a compromised immune system
- History of alcohol, drug, or chemical abuse within 6 months of screening
- Any active acute, subacute, chronic, or recurrent bacterial, viral, or systemic fungal infection or any major episode of infection requiring hospitalization or treatment during screening or treatment with IV antibiotics completed within 4 weeks of the screening visit or oral antibiotics completed within 2 weeks of the screening visit
- History of atypical tuberculosis (TB) or active TB requiring treatment within 2 years prior to screening visit
- Positive TB test at screening unless treated with anti-TB therapy for at least 4 weeks prior to receiving study drug
- History of reactivation or new onset of a systemic infection such as herpes zoster or Epstein-Barr virus within 2 months of the screening visit
- Hepatitis B surface antigen or hepatitis C antibody positivity or chronic viral or autoimmune hepatitis
- History of concurrent serious gastrointestinal disorders such as ulcer or inflammatory bowel disease, Crohn's disease, ulcerative colitis, or other symptomatic lower gastrointestinal conditions
- History of or current cancer or lymphoma
- Uncontrolled diabetes mellitus with elevated glycosylated hemoglobin
- Macrophage activation syndrome (MAS) within 3 months of the screening visit
- Inadequate hematologic, renal or liver function
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Tocilizumab Tocilizumab Participants will receive SC dose of tocilizumab based on body weight; participants with \<30 kg will receive 162 milligrams (mg) of tocilizumab Q2W and those participants =\>30 kg will receive 162 mg of tocilizumab QW, for 52 weeks.
- Primary Outcome Measures
Name Time Method Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Tocilizumab Age <2 years: 0 hours(h) on Days(D) 0,84; on D5,14,42,70,85,88,98,182,266, 364. Weight <30kg, Age>=2 years: 0,6,12h on D0,84; on D2,5,14,42,56,70,86,87,88,90,98,182,266,364. Weight >=30kg: 0,6,12h on D0, 91; on D2,4,7,14,28,56,92,93,95,96,98,182,266, 364 Pharmacokinetics: Maximum Plasma Concentration (Cmax) of Tocilizumab Age <2 years: 0h on D0,84; on D5,14,42,70,85,88,98,182,266,364. Weight <30 kg, Age >=2 years: 0,6,12h on D0,84; on D2,5,14,42,56,70,86,87,88,90,98,182,266,364. Weight >=30 kg: 0,6,12h on D0, 91; on D2,4,7,14,28,56,92,93,95,96,98,182,266,364 Pharmacokinetics: Minimum Plasma Concentration (Cmin) of Tocilizumab Weight <30 kg: predose (0h) on Days 0 and 84. Weight >= 30 kg: predose (0h) on Days 0 and 91
- Secondary Outcome Measures
Name Time Method Pharmacodynamics: Soluble IL-6 Receptor (sIL-6R) Levels Age<2 years: 0h on Days 0,84; Days 5,14,42,70,85,88,98,182,266,364. Weight <30 kg, Age >=2 years: 0,6,12h on Days 0,84; Days 2,5,14,42,56,70,86,87,88,90,98,182,266,364. Weight >=30kg: 0,6,12h on Days 0,91;Days 2,4,7,14,28,56,92,93,95,96,98,182,266,364 Pharmacodynamics: Serum Interleukin-6 (IL6) Levels Age<2 years: 0h on Days 0,84; Days 5,14,42,70,85,88,98,182,266,364. Weight <30 kg, Age >=2 years: 0,6,12h on Days 0,84; Days 2,5,14,42,56,70,86,87,88,90,98,182,266,364. Weight >=30kg: 0,6,12h on Days 0,91;Days 2,4,7,14,28,56,92,93,95,96,98,182,266,364 Pharmacodynamics: Serum C-Reactive Protein (CRP) Levels Age <2years: Days 0,14,28,42,70,84,98,126, 154,182,210,238,266,294,322,350,364. Weight <30 kg, Age >=2years: Days 0,14,28,42,70, 98,126,154,182,210,238,266,294,322,350,364. Weight >=30kg: Days 0,7,14,21,28,42, 56,70,84,91,95,96,98,182,266,294,322,350,364 Pharmacodynamics: Serum Erythrocyte Sedimentation Rate (ESR) Age <2years: Days 0,14,28,42,70,84,98,126, 154,182,210,238,266,294,322,350,364. Weight <30 kg, Age >=2years: Days 0,14,28,42,70, 98,126,154,182,210,238,266,294,322,350,364. Weight >=30kg: Days 0,7,14,21,28,42, 56,70,84,91,95,96,98,182,266,294,322,350,364 Pharmacodynamics: Percentage of Participants with Anti-Tocilizumab Antibodies Age <2 years: Days 0, 84, 182, 266, 364. Weight <30 kg, Age >=2 years: Days 0, 84, 182, 266, 364. Weight >=30 kg: Days 0, 91, 182, 266, 364 Safety: Percentage of Participants with At Least 1 Adverse Event 57 weeks
Trial Locations
- Locations (42)
Hackensack University Medical Center; Pediatric Rheumatology
🇺🇸Hackensack, New Jersey, United States
Ann & Robert H. Lurie Children's Hospital of Chicago; Division of Rheumatology
🇺🇸Chicago, Illinois, United States
Cleveland Clinic Fndn
🇺🇸Cleveland, Ohio, United States
The University of Chicago;Department of Pediatrics
🇺🇸Chicago, Illinois, United States
Hospital de Ninos de la Santisima Trinidad; Reumatologia Infantil
🇦🇷Cordoba, Argentina
Charité Campus; Virchow Klinikum Berlin
🇩🇪Berlin, Germany
Arkansas Children's Hospital Research Institute
🇺🇸Little Rock, Arkansas, United States
Hospital Infantil de México "Federico Gomez"; Rheumatology
🇲🇽Mexico, Mexico
Alder Hey Children's NHS Foundation Trust
🇬🇧Liverpool, United Kingdom
Nottingham Children's Hospital
🇬🇧Nottingham, United Kingdom
Duke University
🇺🇸Durham, North Carolina, United States
Cliditer SA de CV
🇲🇽Miexico City, Mexico
Connecticut Children's Medical Center; 5E Clinical Trials Unit
🇺🇸Hartford, Connecticut, United States
Levine Children's Hospital; Divison of Pediatric Rheumatology; Department of Pediatrics
🇺🇸Charlotte, North Carolina, United States
Cincinnati Children'S Hospital Medical Center; Division of Rheumatology
🇺🇸Cincinnati, Ohio, United States
University of Utah; Immunology/Rheumatology/Allergy
🇺🇸Salt Lake City, Utah, United States
Seattle Children's Hospital
🇺🇸Seattle, Washington, United States
Royal Children'S Hospital; Paediatric Rheumatology
🇦🇺Parkville, Victoria, Australia
Hospital das Clinicas - FMUSP Ribeirao Preto; Pediatria - Imunologia e Reumatologia
🇧🇷Ribeirao preto., SP, Brazil
Westmead Hospital; Paediatric Rheumatology
🇦🇺Westmead, New South Wales, Australia
Hospital das Clinicas - FMUSP; Instituto da Crianca - Reumatologia
🇧🇷Sao Paulo, SP, Brazil
Hospital Gral de Niños Pedro Elizalde
🇦🇷Buenos Aires, Argentina
Universidade Federal de Sao Paulo - UNIFESP
🇧🇷Sao Paulo, SP, Brazil
Alberta Children'S Hospital
🇨🇦Calgary, Alberta, Canada
Hospital For Sick Children
🇨🇦Toronto, Ontario, Canada
Uniklinikum Freiburg Zentrum für Kinder- und Jugendmedizin; Pädiatrische Infektio- u. Rheumatologie
🇩🇪Freiburg, Germany
Irccs Ospedale Pediatrico Bambin Gesu - Dip. Di Medicina
🇮🇹Roma, Lazio, Italy
CH de Bicêtre; Pediatrie Generale
🇫🇷Le Kremlin Bicêtre, France
Asklepios Klinik; Zentrum fuer Allgemeine Paediatrie und Neonatologie
🇩🇪Sankt Augustin, Germany
Nuovo Ospedale Pediatrico Meyer; Reumatologia - Clinica Pediatrica 1°
🇮🇹Firenze, Toscana, Italy
Istituto Giannina Gaslini-Ospedale Pediatrico IRCCS
🇮🇹Genova, Liguria, Italy
FSBI "Scientific Research Institute of Rheumatology" of russian Academy of Medical Sciences
🇷🇺Moscow, Russian Federation
Hospital Universitario Dr. Jose Eleuterio Gonzalez; Pediatria
🇲🇽Monterrey, Mexico
Hospital de La Paz; Unidad de Reumatologia Pediatrica
🇪🇸Madrid, Spain
Hospital Sant Joan De Deu; Servicio de Reumatologia Pediatrica
🇪🇸Esplugas DE Llobregat, Barcelona, Spain
Hospital Ramon y Cajal ; Servicio de Reumatologia
🇪🇸Madrid, Spain
Hospital Infantil Universitario Niño Jesus, Servicio Reumatologia
🇪🇸Madrid, Spain
SI Sceintific children health center RAMS
🇷🇺Moscow, Russian Federation
Hospital Universitario la Fe: Servicio de Reumatologia Pediatrica
🇪🇸Valencia, Spain
Bristol Royal Hospital For Children
🇬🇧Bristol, United Kingdom
Great Ormond Street Hospital; Somers Clinical Research Facility
🇬🇧London, United Kingdom
Children'S Hospital of Eastern Ontario
🇨🇦Ottawa, Ontario, Canada